Thursday, November 20, 2008
Print Current Session:
|
|
Thursday
SESSION XV:
CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) (5-MINUTE FAST PACED TALKS)
Moderators:Mark H. Wholey, M.D. , Thomas S. Riles, M.D.
|
|
SESSION XV SCHEDULE | |
2:06 PM - 2:12 PM | Debate I: ACST The 10-Year Results: We Do Not Need A Trial Of CAS And CEA vs. Best Medical Treatment (Vintage 2008) With Asymptomatic Patients |
Presenters(s): Alison Halliday, M.S., F.R.C.S. | |
2:13 PM - 2:19 PM | Debate I: Any Randomized Trial Comparing CAS To CEA Must Include A Best Current Medical Treatment Arm Or It Is Worthless |
Presenters(s): Peter R.F. Bell, M.D., F.R.C.S., D.S.C., K.B.E. | |
2:20 PM - 2:25 PM | Will The TACIT Trial Comparing CAS And CEA To Best Medical Therapy In Asymptomatic Patients Ever Take Place?: What Is Its Status? |
Presenters(s): John H. Rundback, M.D., F.S.I.R., F.A.H.A. | |
2:26 PM - 2:31 PM | New Findings From The SPACE Trial: CEA Is Better Than CAS In Symptomatic Patients Over 68; And The SPACE Investigators Will Perform A Three-Armed Trial (SPACE II) Comparing CAS To CEA To Best Medical Treatment: When Will We Have An Answer? |
Presenters(s): Dittmar Boeckler, M.D. / Hans-Henning Eckstein, M.D., Ph.D. | |
2:32 PM - 2:37 PM | Timing Of Strokes In The EVA-3S And Other Trials Indicate That Embolic (Cerebral) Protection Devices Are Often Not Protective When They Need To Be |
Presenters(s): Emmanuel M. Houdart, M.D. | |
2:38 PM - 2:43 PM | When After A TIA Is The Risk Of Stroke Maximal And When After A TIA Should A Patient Be Treated By CEA, CAS Or Medical Treatment? |
Presenters(s): Ross Naylor, M.D., F.R.C.S. | |
2:44 PM - 2:49 PM | Debate II: CAS Can Be Performed Safely And Effectively In Patients Over 75 |
Presenters(s): Max Amor, M.D. | |
2:50 PM - 2:55 PM | Debate II:CAS Should Be Outlawed In Patients Over 75 |
Presenters(s): Bruce A. Perler, M.D., M.B.A. | |
2:56 PM - 3:06 PM | Panel Discussion |
Moderator(s): Peter Gaines, M.D. / Mark A. Adelman, M.D. | |
3:06 PM - 3:11 PM | Debate III:EVA-3S Was A Worthless And Misleading Trial |
Presenters(s): Alberto Cremonesi, M.D., FESC | |
3:12 PM - 3:17 PM | Debate III:EVA-3S And SPACE Are Valid Trials: Recently Symptomatic Carotid Stenosis Should Not Be Treated By CAS |
Presenters(s): Jean-Pierre Becquemin, M.D., F.R.C.S. | |
3:18 PM - 3:23 PM | Debate IV: Stent Characteristics And Geometry Are Of Critical Importance In The Outcome Of CAS: Is There Better Stent Technology On The Horizon? |
Presenters(s): Koen Deloose, M.D. / Marc Bosiers, M.D. | |
3:24 PM - 3:29 PM | Debate IV: Stent Characteristics And Geometry Are Only One Of Many Factors Determining The Outcome Of CAS |
Presenters(s): Mark H. Wholey, M.D. | |
3:30 PM - 3:35 PM | The SAPPHIRE Trial Is Seriously Flawed And Does Not Help In Treatment Choices For High Risk Patients |
Presenters(s): Anthony J. Comerota, M.D., FACS, FACC | |
3:36 PM - 3:41 PM | Morbidity And Mortality For CAS Is Higher Than For CEA In U.S. Population Based Studies: A Disturbing Trend |
Presenters(s): John Blebea, M.D. | |
3:42 PM - 3:47 PM | Aggressive Interventions For Chronically Occluded Internal Carotid Arteries: Can They Be Helpful And When? |
Presenters(s): Pedro Puech-Lećo, M.D. | |
3:48 PM - 3:58 PM | Panel Discussion |
END OF SESSION XV | |
previous | next |